30 September 2021 : Clinical Research
Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement
Wei Sheng1ABCDEF*, Hui Qiao1ABCDEF, Zhaozhuo Niu1BCE, Tianyi Wang1BCE, Haoyou Li1CDE, Wenfeng Zhang1CDE, Jiantao Wu1CDE, Xiao Lv1ADEFDOI: 10.12659/MSM.932001
Med Sci Monit 2021; 27:e932001
Table 2 Comparison of cardiac function at different time points between the 2 groups.
Parameters | Time (after surgery) | Levosimendan (n=93) | Control (n=92) | χ2 or t value | P value |
---|---|---|---|---|---|
CO (L/min, mean±SD) | 1 day | 4.5±0.9 | 4.2±0.8 | 2.395 | 0.018 |
3 days | 4.7±1.1 | 4.3±0.9 | 2.705 | 0.008 | |
7 days | 5.2±1.0 | 4.4±1.1 | 5.177 | 0.000 | |
LVEF (%, mean±SD) | 1 day | 51.3±2.2 | 48.3±2.1 | 9.486 | 0.000 |
3 days | 53.5±2.4 | 48.9±2.1 | 13.868 | 0.000 | |
7 days | 55.7±2.5 | 50.5±2.2 | 15.012 | 0.000 | |
BNP (pg/mL, mean±SD) | 1 day | 520.7±47.2 | 986.5±55.1 | 61.772 | 0.000 |
3 days | 420.5±39.6 | 747.3±50.2 | 49.188 | 0.000 | |
7 days | 312.5±34.6 | 455.4±45.2 | 24.161 | 0.000 | |
CO – cardiac output; LVEF – left ventricular ejection fraction; BNP – B-type natriuretic peptide. |